The drug and gene delivery devices market size was estimated at USD 569.38 billion in 2025 and is expected to surpass around USD 1,151.86 billion by 2035 and poised to grow at a compound annual growth rate (CAGR) of 7.3% during the forecast period 2026 to 2035.
AI and ML are accelerating the drug and gene delivery device industry by optimizing formulation and enabling the design of smart targeted delivery systems that respond to physiological cues, reducing the need for trial-and-error testing. The precision of nanoparticles, lipid nanoparticle (LNP) carriers, and gene-editing vectors is crucial for the efficacy of complex therapies such as mRNA vaccines and gene therapies. In the market, AI analyzes vast datasets to personalize treatment regimens, ensuring optimal dosage and sustained release for individual patients, which directly enhances therapeutic outcomes and patient compliance. ML enhances the development of connected drug delivery devices, such as smart inhalers and injection devices, by enabling real-time monitoring and predictive maintenance, lowering overall healthcare costs.
| Report Attribute | Details |
| Market Size in 2026 | USD 610.94 Billion |
| Market Size by 2035 | USD 1,151.86 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 7.3% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | Delivery Type, Method, Vector, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, Uniqure NV |
Based on delivery type, the oral segment dominated the global drug and gene delivery devices market in 2025, in terms of revenue and is estimated to sustain its dominance during the forecast period. The oral drug delivery is the most convenient and most popular route of administration all over the globe. It is economical, pain-free, and self-administered type of delivery where no sterile precautions are involved. Moreover, the development of various therapeutics that can identify the affected cell and can treat that cell without harming the normal cells is exponentially boosting the growth of this segment. Therefore, the rapid growth of the biosimilar, targeted therapeutics, and gene therapies had positively impacted the market growth in the past few years.
On the other hand, the injectable is estimated to be the most opportunistic segment during the forecast period. The technological advancements in the injectable devices has propelled the adoption of the self-injectable devices among the patients. The rising number of diabetic population is fostering the growth of this segment as the diabetic patient need to regularly inject insulin. The increasing popularity of the self-injectors, needle-free injectors, pen-injectors, and auto-injectors has allowed the patients to conveniently administer drugs from the convenience of their home, eliminating the medical assistance. All these factors are estimated to have a significant impact on the drug and gene delivery devices market and will foster the demand for the injectable segment in the forthcoming years.
Based on the method used, gene delivery system is segmented as in situ and ex vivo. Most of the currently approved drugs act by in situ methods. Thus, the in situ segment is currently dominating the industry with the largest share.
High focus on the in situ methods owing to its ease of performance is expected to make it the fastest growing segment in the space. However, the segment growth is expected to impede the low efficiency of transduction procedures.
Viral vectors currently dominate the gene delivery systems market with 4 approved drugs. More than 80% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection. Thus, the viral segment is expected to remain dominant throughout the forecast period.
Viral vectors enable complex procedures involved in transfection procedures such as gene gun, magnetofection, ultrasound, and hydrodynamic. In addition, it has increased the success rate of the gene transfer as compared to its counterpart techniques
North America captured the largest market share in 2022. The presence of a large number of key players and high adoption rate of the advanced methods are the factors driving the industry growth in the region. In addition, high investment in R&D by the U.S. government and industry participants is augmenting the industry growth of the region.
Asia Pacific is expected to show a lucrative growth rate during the forecast period owing to factors such as growing awareness about the novel systems as well as the influx of the international industry players to seek opportunities in the untapped market in the region.
U.S. Drug and Gene Delivery Devices Market Trends
U.S.’s strategic shift toward subcutaneous biologics and high-capacity wearable injectors that support the growing preference for home-based self-administration. The breakthroughs in nanoparticle-based and viral vector systems are enabling highly targeted gene therapies for previously untreatable conditions like retinal dystrophy. The industry’s commitment to sustainable inhaler technologies ensures that these life-saving advancements also meet the increasing global demand for reduced greenhouse gas emissions.
China Drug and Gene Delivery Devices Market Trends
China’s shift toward injection devices, with pens and autoinjectors, to meet the rising demand for insulin and biologic self-administration. The boom in gene delivery technologies is essential for the region's expanding pipeline of precision oncology and rare disease therapeutics. Strategic investments in AI-driven smart manufacturing and digital integration are also enhancing device efficiency and patient data tracking across the healthcare system.
This stage involves the conceptualization, design, and prototyping of innovative delivery devices, including smart pumps, microneedle patches, and viral vector systems.
Key Players: Medtronic plc, Moderna Inc., Intellia Therapeutics, CRISPR Therapeutics, Voyager Therapeutics, Inovio Pharmaceuticals.
This stage secures specialized, high-grade materials, including medical-grade polymers, lipid nanoparticles (LNPs), viral vectors, and advanced electronics for smart devices. Suppliers must adhere to strict quality standards to ensure biocompatibility and device functionality.
Key Players: Merck KGaA (MilliporeSigma), Thermo Fisher Scientific Inc., Lonza Group Ltd., Catalent, Inc., Danaher Corporation (Cytiva).
This crucial, time-intensive stage ensures compliance with stringent international regulations (FDA, EMA) regarding safety, efficacy, and sterility of the delivery systems. It includes clinical trials, validation of delivery performance, and obtaining approvals before market launch.
Key Players: Novartis AG, F. Hoffmann-La Roche Ltd.
Pfizer contributes to the drug and gene delivery market by leveraging its large-scale manufacturing capabilities to produce mRNA-based vaccines and by investing in AI-driven RNA delivery technologies, such as their collaboration with UT Southwestern.
Roche contributes through its "platform innovation" approach, integrating diagnostic tools with novel biologics and advancing RNA-targeted therapeutics and gene therapies.
J&J (Innovative Medicine) focuses on advanced drug delivery systems, particularly in oncology, including the development of innovative intravesical drug delivery systems for bladder cancer (INLEXZO) and subcutaneous delivery options (RYBREVANT).
Novartis contributes to the gene delivery market through its leadership in gene therapy and radioligand therapy platforms, specializing in delivering targeted cures for rare diseases and oncology.
Bayer contributes to drug delivery by advancing targeted drug delivery technologies, including molecular imaging and smart delivery platforms, which are critical for delivering complex drugs to specific body tissues.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the Drug And Gene Delivery Devices market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the drug and gene delivery devices market
By Delivery Type
By Method
By Vector
By Region
Drug and Gene Delivery Devices Market
Download Sample
Request Customization
Request Customization
Download Sample